BC
AMAG

Broadfin Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Broadfin Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-100,000
Closed -$1.16M – 54
2019
Q3 		$1.16M Buy
+100,000
New +$1.05M 0.21% 43
2018
Q2 		– Sell
-598,800
Closed -$12.1M – 65
2018
Q1 		$12.1M Buy
+598,800
New +$10.1M 1.88% 19
2016
Q1 		– Sell
-300,000
Closed -$9.06M – 88
2015
Q4 		$9.06M Buy
+300,000
New +$9.69M 0.56% 49
2015
Q1 		– Sell
-573,530
Closed -$24.4M – 89
2014
Q4 		$24.4M Sell
573,530
-937,245
-62% -$33.9M 2.13% 14
2014
Q3 		$48.2M Sell
1,510,775
-450,000
-23% -$9.6M 5.05% 3
2014
Q2 		$40.6M Buy
1,960,775
+1,093,658
+126% +$20.2M 3.96% 6
2014
Q1 		$16.8M Buy
+867,117
New +$18.4M 1.63% 19

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Broadfin Capital's AMAG Position: Q4 2019 in Review

Broadfin Capital sold out of AMAG Pharmaceuticals (AMAG) in Q4 2019, closing a stake of 100,000 shares — an estimated $1.16M sold.

Broadfin Capital first reported a position in AMAG in Q1 2014 and held it in 7 quarters. The position peaked at $48.2M in Q3 2014. 134 funds tracked by Wall St. Rank hold AMAG as of Q4 2019.

  • Broadfin Capital reported no remaining AMAG Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 100,000 AMAG Pharmaceuticals shares in Q4 2019, an estimated $1.16M.
  • Broadfin Capital first reported a position in AMAG Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Broadfin Capital's AMAG Pharmaceuticals position peaked at $48.2M in Q3 2014.
  • 134 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.